Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: Delta sleep-inducing peptide
Peptide or peptide-related · Peptide or peptide derivative
Detailed molecular class: Neuropeptide candidate
Supplied sequence or chemical reference
See identity note; no supplier sequence accepted as verification.
Mechanism
Proposed sleep modulation; mechanism is not a validated treatment indication.
Evidence and critical reading
Reported scientific and empirical uses
Sleep and circadian rhythms
Handbooks describe sleep onset and deep sleep, alone or with Epitalon. Sleep initiation, sleep architecture, daytime functioning and long-term safety need separate evaluation.
Human evidence
Small double-blind insomnia trial found weak/selective effects, not major therapeutic benefit.
Preclinical evidence
Sleep-related experimental effects cannot establish chronic insomnia treatment.
Critical reading and limitations
The insomnia trial reviewed included 16 participants and selective findings that do not establish a broadly effective therapy. Handbooks propose differing frequencies and cycles; nighttime combinations do not inherit validation from individual studies.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Empirical handbook
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
100 mcg · Amount per administration
- Frequency
- Daily per source.
- Duration
- Not stated on selected page.
- Route
- Subcutaneous
- Context
- Described sleep promotion.
- Presentation
- 1 mg/mL; 3-mL vial per source.
- Interpretation
- Does not validate efficacy or safety of this regimen; attributed to the handbook.
manual01 · Page 45 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
Safety of community exposure and combinations with sedatives has not been established; do not claim a proven interaction where none was characterized.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID1299794 · Double-blind matched-pair placebo study
Chronic insomnia.
Intravenous, brief exposure.
Weak selective effects; authors did not expect major therapeutic benefit.
Does not validate handbook SC dosing or an Epitalon stack.
n = 16
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
DSIP · 0 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry querySource issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PMID1299794
Bes F, Hofman W, Schuur J, Van Boxtel C.
October 16, 2026
- R06
- R18
- manual01
Peptide Handbook — James B. LaValle, Gordon Crozier, Joseph P. Cleaver and Andrew Heyman
James B. LaValle; Gordon Crozier; Joseph P. Cleaver; Andrew Heyman
October 16, 2026
Bibliographic attribution only. The supplied handbook is a secondary empirical practice source, not clinical verification. Private source files and supplier/download destinations are not provided here.
- pdf01
PEPNEXA 2.pdf
October 16, 2026
- pdf02
ELLA PEPTIDES.pdf
October 16, 2026
- pdf03
zlz list 26.8.5.pdf
October 16, 2026
- pdf05
PEPNEXA.pdf
October 16, 2026
- pdf07
US Peptide MangerCorp(1).pdf
October 16, 2026
- pdf09
PeptideFactory.pdf
October 16, 2026